Ampio Pharmaceuticals, Inc.
AMPE
$0.01
-$0.14-96.39%
OTC PK
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -50.41% | -64.00% | -62.53% | 16.33% | -56.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -17.99% | -75.53% | -68.72% | -37.69% | -70.73% |
| Operating Income | 17.99% | 75.53% | 68.72% | 37.69% | 70.73% |
| Income Before Tax | 7.48% | 80.83% | 33.77% | 29.42% | 64.33% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 7.48% | 80.83% | 33.77% | 29.42% | 64.33% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 7.48% | 80.83% | 33.77% | 29.42% | 64.33% |
| EBIT | 17.99% | 75.53% | 68.72% | 37.69% | 70.73% |
| EBITDA | 12.03% | 73.95% | 67.03% | 37.15% | 71.91% |
| EPS Basic | 15.79% | 82.03% | 33.86% | 29.52% | 67.63% |
| Normalized Basic EPS | 15.75% | 74.26% | 33.86% | 25.41% | 67.63% |
| EPS Diluted | 27.88% | 84.78% | 72.38% | 42.98% | 72.10% |
| Normalized Diluted EPS | 15.75% | 74.26% | 33.86% | 25.40% | 67.63% |
| Average Basic Shares Outstanding | 9.87% | 6.71% | 0.15% | 0.15% | 10.19% |
| Average Diluted Shares Outstanding | 9.87% | 6.71% | 0.15% | 0.13% | 10.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |